The discovery and design of small molecules that meet specific target endpoints in drug discovery is a formidable challenge. Traditionally, structure-based hit discovery involves computationally screening commercially available or proprietary libraries via docking into the binding pocket, with expected hit rates between 0.02% and 34.8% . However, the rapid expansion of virtual libraries 2 renders brute force